Introduction {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC) is a malignant and highly lethal neoplasm of unknown etiology and is usually diagnosed at advanced stages ([@B1]). The currently available surgical interventions and chemotherapeutic regimes are unable to provide the desired impact on disease outcomes, and there is a clear, dismal prognosis, as 70--80% of patients will succumb to this disease during the first 2 years post-diagnosis ([@B2]). PDAC is the fourth leading cause of cancer-related deaths worldwide ([@B3]) and is expected to become the second leading cause of cancer-related deaths by 2025, due both to the improved outcome of other malignancies, and on the stagnation in outcome improvement for PDAC over the past 30 years ([@B4]--[@B6]). Modifiable and non-modifiable risk factors for PDAC have an unconvincing molecular association with the disease. Modifiable factors seem to distribute haphazardly around the world, and the classic ones, such as tobacco, diabetes, gallstones (GS) and alcohol intake, are absent in a significant proportion of patients ([@B7], [@B8]). The development of interventions that successfully reduce the incidence of this lethal malignancy and improve its outcome is limited by the scarce knowledge of the molecular factors that may play a role in the complex process of PDAC carcinogenesis ([@B9]). Hence, any effort to better understand PDAC carcinogenesis, or to unravel novel therapies, may be the starting point in driving future clinical interventions.

Bacteria have been associated with benign and malignant disease, and bacterial carcinogenesis is a process still being characterized in detail. The knowledge from such study may be the starting point to drive clinical interventions focused on cancer prevention. The carcinogenesis associated with viruses is based on the integration of the viral genome into the host DNA (i.e., Human Papilloma Virus, Epstein-Barr) and has been extensively studied and characterized ([@B10]). Conversely, bacterial carcinogenesis is a phenomenon thought to be the result of epithelial cells\' chronic exposure to a pro-inflammatory milieu exacerbated by bacteria ([@B11], [@B12]). However, this pro-inflammatory, physiopathological mechanism cannot explain convincingly by itself the development of carcinomas in the gastrointestinal and biliary tract, as inflammatory phenomena regularly occur throughout the human lifespan, and just a few human beings develop malignant neoplasms.

The biliary tract including intra-pancreatic bile ducts, is a semi-closed duct system possessing its own microbiota ([@B13]--[@B15]), lined by cholangiocytes, and in constant contact with bile. Cholangiocytes or cholangiocyte like cells are the proposed cell of origin for a range of biliary tract carcinomas, also named cholangiocarcinoma, in gallbladder, and intra or extrahepatic bile ducts ([@B16]). PDAC derives from ductal cholangiocytes or transdifferentiated acinar-to-ductal cholangiocytes ([@B17], [@B18]) covering intra-pancreatic bile ducts (ductal carcinoma), so from the histopathological point of view PDAC and biliary tract carcinomas are not very different ([@B19]). In the case of PDAC, local microbiota may have effects on oncogenesis ([@B20]) and long term survival ([@B21]), but most of the surveys associating PDAC and bacteria demonstrate spurious associations due to inconsistent isolation of specific bacterial species and the lack of a molecular basis for bacteria-induced carcinogenesis ([@B22], [@B23]). Being part of the biliary tract microenvironment, bacteria must contribute to bile protein pool composition in a similar way to cholangiocytes. As cholangiocytes and bacteria are in permanent contact with bile, we hypothesize that bile-associated protein changes could reflect bile duct system alterations in the microenvironment sufficient to transform benign epithelial cells into a malignant phenotype.

Bile is stored and concentrated in the gallbladder, which is a clean reservoir where this biological fluid can be extracted for protein analysis ([@B24]). In research, bile samples are typically taken from the distal portion of the biliary tract during endoscopic interventions, such as endoscopic retrograde cholangiopancreatography (ERCP) ([@B25]). However, the inflammatory process associated with biliary obstruction in most PDAC patients may alter bile protein composition in the distal portion of the biliary tract and limit the finding of meaningful biological information. The lack of meaningful biological findings hinders the development of a specific model of carcinogenesis for the biliary tract that takes into account its unique physiological conditions, and the interplay of human and bacterial proteins.

We analyzed samples of human bile taken directly from the gallbladder, and not by ERCP, exposed to a pancreatic tumor vs. non-tumor microenvironment. The aim of the study, once samples were analyzed by mass spectrometry, was to find meaningful biological information through pathway inference analysis of the identified human and bacterial proteins. Biological pathway analysis was initially performed using the g:Profiler platform to compare and generate a complete panorama of the gene-protein sets being analyzed, including over-represented KEGG biological pathways ([@B26]). Then, we directly analyzed each protein set using the KEGG Mapper Reconstruct Pathway module ([@B27]), focusing on over-represented pathways in g:Profiler for human proteins, and prokaryote interaction pathways for bacterial proteins. KEGG has become a world reference database for assisting biological interpretations of molecular data sets. Currently, biological pathway analyses are one of the most reliable strategies for mechanistic insights into omics data, since the kind of evidence that supports the statistical modeling is always experimental and manually curated ([@B28]). Thus, in this study, using a paradigm shifting metaproteomic approach, we aimed to unravel novel and meaningful biological information that may contribute to a better understanding of PDAC bacteria-induced carcinogenesis, proposing a new carcinogenesis model for the biliary tract.

Materials and Methods {#s2}
=====================

Ethics and Sample Acquisition
-----------------------------

The Institutional Human Ethics Committee at CES University and Clinic approved this study, and patients must give informed consent. Samples were de-identified before performing proteomic analysis. A surgical pathologist collected a total of 20 gallbladder bile samples; seven from patients with gallstones (GS), and 13 from patients with PDAC arising from the head of the pancreas. All patients were Colombians, and residents of Medellín (Colombia). For GS patients, bile was obtained in the operating room immediately after laparoscopic extraction of the gallbladder, puncturing the gallbladder fundus with a syringe, and aspirating at least 5 mL of bile. For PDAC patients, bile was similarly collected, by aspirating bile with a syringe from the gallbladder pancreatoduodenectomy specimens were sent to the pathology lab for a cryosection margin report. Immediately after collection, bile samples were transported on ice, aliquoted, and stored at −80°C until further analysis. Patients with a clinical history of previous malignant neoplasms, chemotherapy, prior biliary tract surgery or biliary stent placement, HIV, pregnancy, chronic pancreatitis, choledocholithiasis, cystic fibrosis, hepatolithiasis, primary biliary cholangitis, liver cirrhosis, primary sclerosing cholangitis, or acute cholecystitis were excluded from this study.

Protein Extraction
------------------

Bile samples were thawed at room temperature and processed as previously described with slight modifications ([@B29]). Briefly, 1 mL of bile was centrifuged for 10 min at 4°C and 3,000 rpm, and 1 mL of TRI reagent and 1 mL of chloroform were added. The mix was incubated for 5 min at room temperature (20--25°C) and centrifuged for 15 min at 4°C and 12.000 xg to separate proteins. Avoiding the central lipid layer, remaining tube contents (supernatant + pellet) were transferred to a new tube. Then, 1,200 μL of acetone was added, mixed, incubated for 4 h, and centrifuged for 15 min at 4°C at 12,000 xg. Acetone was discarded, and the tubes were dried at room temperature, after which 200 μL of reconstituting buffer was added to the pellet, and the solution dried and lyophilized.

Proteomic Analyses
------------------

Proteomic analysis was performed by Creative Proteomics (Ramsey Road, Shirley, NY 11967, USA), briefly, the techniques used are described as follows:

### Sample Preparation for Proteomic Analysis

Total proteins were precipitated from the protein solution using methanol and chloroform. Approximately 10 μg of total protein was dissolved in 6 M urea aqueous solution and was denatured with 10 mM DL-dithiothreitol, incubated at 56°C for 1 h, followed by alkylation with 50 mM iodoacetamide, and incubated for 60 min at room temperature, protected from light. Next, 500 mM ammonium bicarbonate (ABC) was added to the solution to make a final concentration of 50 mM ABC with a pH of 7.8. Promega Trypsin was added to the protein solution for digestion at 37°C for 15 h. The generated peptides were further purified with the C18 SPE column (Thermo Scientific) to remove salt. Samples were dried in a vacufuge and stored at −20°C until use.

### Nano Liquid Chromatography

An Easy-nLC1000 (ThermoFisher Scientific, USA) coupled to a 100 μm × 10 cm in-house made column packed with a reversed-phase ReproSil-Pur C18-AQ resin (3 μm, 120 Å, Dr. Maisch GmbH, Germany) was used. A sample volume of 5 μL was loaded, with a total flow rate of 600 nL/min, and a mobile phase of A: 0.1% formic acid in water; and B: 0.1% formic acid in acetonitrile. The analytical separation was run using a gradient: from 6 to 9% B for 15 min, from 9 to 14% B for 20 min, from 14 to 30% B for 60 min, from 30 to 40% B for 15 min and from 40 to 95% B for 3 min, eluting with 95% B for 7 min.

### Mass Spectrometry and Data Analysis

An Orbitrap Q Exactive™ mass spectrometer (Thermo Fisher Scientific, USA) set on a spray voltage of 2.2 kV and a capillary temperature of 270°C was used. Mass spectrometry resolution was set to 70,000 at 400 m/z and precursor m/z range: between 300.0 and 1800.0. The production scan range starts from m/z 100, activated by collision-induced dissociation (CID), and an isolation width of 3.00. The raw files were analyzed and searched against the human protein database from Uniprot using Maxquant (1.5.6.5). The parameters were set as follows: the protein modifications were carbamidomethylation (C) (fixed), oxidation (M) (variable); the enzyme specificity was set to trypsin; the maximum missed cleavages was set to 2; the precursor ion mass tolerance was set to 10 ppm, and MS/MS tolerance was 0.6 Da.

Human and Bacteria Peptide-Protein List Selection for Analysis
--------------------------------------------------------------

Peptide-protein analysis was performed at ICMT-CES University. Contaminants, albumin, hemoglobin related peptides, and peptides with zero intensity were eliminated from the full human and bacteria list of peptides-proteins. The identifiers of protein were standardized, missing gene names were manually completed, and protein taxonomy was verified.

Then, the full list of shared proteins was adapted to meet the requirements of the Prostar platform online version 1.18.1 ([@B30]), seeking for differentially abundant human and bacterial proteins among groups (GS vs. PDAC). The intensity values were normalized with the mean centering method without including variance reduction. Partially observed values were imputed using the SLSA (Structured Least Squares Adaptive) method. The hypothesis test was performed using the Student\'s *t*-test, considering a logarithmic change of 2.5 and adjusting the false discovery rate to 0.42% (*p*-value = 0.00316). The biological validity of imputing non-existent values for non-observed proteins, in order to compare the exclusive groups of proteins, was explored. However we chose to perform the analysis based only on observed values in the two groups, GS and PDAC (shared proteins).

For further qualitative analysis, all the human protein lists of the total, exclusive and differentially abundant proteins from GS and PDAC patients ([Figure 1](#F1){ref-type="fig"}) were included in the retrieve ID/mapping module of the Universal Protein consortium resource (Uniprot <http://www.uniprot.org/>, UniProt release 2019_10). Then, in order to provide mechanistic insights into the biologically integrated function, Uniprot-standardized human protein lists of entries for each group were analyzed in the g:Profiler web page (<https://biit.cs.ut.ee/gprofiler/gost>) ([@B26]). g:Profiler allows a multi-query approach, which performs an over-representative functional analysis of multiple protein-gene lists, comparing proteins among groups. Default options were maintained in g:Profiler, adding no electronic gene ontology annotations, and Bonferroni correction for multiple test adjustments. Significant, adjusted, over-represented pathways (*p*-values \< 0.01), were used for further analysis in the KEGG Mapper Reconstruct Pathway. KEGG identifiers were obtained from the Uniprot FASTA file of the total, exclusive, and differentially abundant protein list, through BlastKoala (KEGG Orthology and Links Annotation version 2.2 <https://www.kegg.jp/blastkoala/>) ([@B31]). KEGG Mapper Reconstruct Pathway allows visualization and comparison of proteins in signaling pathways to identify qualitative and quantitative differences without coupled statistical analysis. (<https://www.genome.jp/kegg/tool/map_pathway.html>) ([@B27]). On the other hand, useful drugs were explored using the functional database DrugBank through WebGestalt (WEB-based GEne SeT AnaLysis Toolkit updated on 01/14/2019 <http://www.webgestalt.org/>) ([@B32]), by performing an over-representation analysis (ORA), using the database Drugbank and setting the false discovery rate at \<0.01 ([@B32]) with Bonferroni correction for multiple test adjustments.

![Identified peptides-proteins per group and origin. The figure depicts peptides-proteins identified from human **(A)**, and bacteria **(B)**. GS, gallstones; PDAC, pancreatic ductal adenocarcinoma.](fonc-10-01032-g0001){#F1}

The biological context was analyzed as a whole for the total protein groups by correlating findings with the specific proteins identified for each condition. Many biological pathways were enriched over the Bonferroni p-adjusted value threshold in the total protein groups, but just three of them were related to bacterial infection ([Figure 2](#F2){ref-type="fig"}).

![Pipeline of proteins data sets analysis and summary or relevant findings. GS, gallstones; PDAC, pancreatic ductal adenocarcinoma; DA, differentially abundant; KEGG, Kyoto encyclopedia of genes and genomes; IL-8, interleukin 8; ATB, antibiotics. \*Small sample microbiota metagenome inference analysis (unpublished results). \*\*Not statistical analysis associated.](fonc-10-01032-g0002){#F2}

For bacterial proteins, the same protocol for contaminant elimination, quality control, and differential abundance analysis was performed as for human proteins. We did not use g:Profiler for bacterial protein analysis because this platform is not conceived for multi-species analysis. The bacterial protein lists of total and exclusive proteins from GS and PDAC patients were also included in the retrieve ID/mapping module of the Universal Protein consortium resource. KEGG identifiers were obtained using BlastKoala from the Uniprot FASTA files, and we focused our attention on prokaryote interaction signaling pathways during the analysis in KEGG Mapper Reconstruct Pathway ([@B33]).

Results {#s3}
=======

A total of 20 bile samples extracted from gallbladders were analyzed, seven of which were taken from patients with GS (mean age of 48 years) ([Table 1](#T1){ref-type="table"}), and 13 from patients with PDAC (mean age of 56 years). All the patients were residents in Medellín and none of the patients presented clinical or histopathological signs of acute inflammation.

###### 

Clinical and demographic characteristics of patients.

  **Diagnosis**   **Age**   **Sex**   **Gallstones**   **Pathologic Staging**   **Perineural Invasion**
  --------------- --------- --------- ---------------- ------------------------ -------------------------
  GS              66        M         (+)              NA                       NA
  GS              52        F         (+)              NA                       NA
  GS              32        F         (+)              NA                       NA
  GS              42        M         (+)              NA                       NA
  GS              55        F         (+)              NA                       NA
  GS              48        M         (+)              NA                       NA
  GS              46        F         (+)              NA                       NA
  PDAC            52        F         (+)              pT2N0                    (+)
  PDAC            58        M         (+)              pT3N1                    (+)
  PDAC            66        M         (-)              pT2N1                    (+)
  PDAC            46        M         (-)              pT3N1                    (+)
  PDAC            68        M         (-)              pT3N1                    (+)
  PDAC            60        M         (-)              pT3N1                    (+)
  PDAC            35        M         (-)              pT2N1                    (+)
  PDAC            60        F         (+)              pT2N0                    (+)
  PDAC            56        F         (-)              pT3N0                    (+)
  PDAC            58        M         (-)              pT3N1                    (+)
  PDAC            61        F         (+)              pT2N1                    (+)
  PDAC            62        F         (-)              pT3N0                    (+)
  PDAC            55        M         (-)              pT3N1                    (+)

*GS, gallstones; PDAC, pancreatic ductal adenocarcinoma; M, male; F, female*.

After excluding peptides that were unassociated with any known proteins, a total of 10,834 human peptides were identified with a mean of 542 peptides per sample, 8,877 peptides in the GS group and 7,413 in the PDAC group. Peptides were associated with a total of 2,198 human proteins, 1,837 proteins in the GS group, and 1,932 proteins in the PDAC group. Upon comparison, a total of 1,571 proteins were common to both groups, while 266 proteins were exclusively found in the GS group, and 361 proteins in the PDAC group ([Figure 1A](#F1){ref-type="fig"}). For bacteria, we identified a total of 934 peptides with a mean of 46 peptides per sample, 494 in the GS group and 629 in the PDAC group. Those peptides were associated with a total of 748 bacterial proteins, 377 proteins in the GS group and 471 in the PDAC group. We found 100 proteins shared among the two groups, with 277 exclusive proteins remaining in the GS group and 371 in the PDAC group ([Figure 1B](#F1){ref-type="fig"}). Quantitative differential abundance analysis using Prostar revealed among the shared proteins within the human and bacteria groups, 123 differentially abundant human proteins, 81 in the GS group and 42 in the PDAC group, and no differentially abundant bacterial proteins.

Human Protein Over-Representation Analysis
------------------------------------------

The g:Profiler platform was used for the over-representation analysis in KEGG signaling pathways. Analyzing the total list of proteins, the platform identified from the 1,837 proteins in the GS group 1,832 (99.7%) and from 1,932 in the PDAC group 1,929 (99.8%). Regarding exclusive and differentially abundant proteins, the platform identified 100% of proteins in the GS and PDAC groups. In the total protein lists, we found five over-represented pathways in the GS group and seven in the PDAC group ([Table 2](#T2){ref-type="table"}), and in the exclusive protein lists, we identified one over-represented pathway in each group: phagosome in the GS group and metabolic pathways in the PDAC group. The analysis of the differentially abundant list of proteins revealed just one over-represented pathway in the GS group: vasopressin-regulated water reabsorption.

###### 

g:Profiler over-represented signaling pathway in human proteins.

  **Total Proteins GS** **=** **1837 PDAC** **=** **1932**                                        
  ------------------------------------------------------------------------ ------------ --------- ---------
  Pertussis                                                                KEGG:05133   0.23886   0.00061
  Proximal tubule bicarbonate reclamation                                  KEGG:04964   0.00094   0.06026
  Cholesterol metabolism                                                   KEGG:04979   0.03619   0.00105
  Drug metabolism---other enzymes                                          KEGG:00983   0.01750   0.00111
  Amino sugar and nucleotide sugar metabolism                              KEGG:00520   0.00116   0.03220
  Sulfur metabolism                                                        KEGG:00920   0.00196   0.04153
  Glyoxylate and dicarboxylate metabolism                                  KEGG:00630   0.03702   0.00203
  Legionellosis                                                            KEGG:05134   0.01740   0.00231
  Adherens junction                                                        KEGG:04520   0.00280   0.05119
  Arginine and proline metabolism                                          KEGG:00330   0.02670   0.00305
  Shigellosis                                                              KEGG:05131   0.01019   0.00575
  **Exclusive Proteins GS** **=** **266 PDAC** **=** **361**                                      
  Phagosome                                                                KEGG:04145   0.00011   0.04876
  Metabolic pathways                                                       KEGG:01100   1         0.00142
  **Differentially Abundant Proteins GS** **=** **81 PDAC** **=** **42**                          
  Vasopressin-regulated water reabsorption                                 KEGG:04962   0.00066   1

*KEGG, Kyoto Encyclopedia of Genes and Genomes; GS, gallstones; PDAC, pancreatic ductal adenocarcinoma*.

The over-represented pathways were analyzed in KEGG Mapper Reconstruct Pathway focusing our attention in the three g:Profiler over-represented pathways in the PDAC total protein group related to the bacterial infections Shigellosis, Pertussis, and Legionellosis. Analyzing the list of proteins in these three pathways ([Table 3](#T3){ref-type="table"}), it is notable that IL-8 (interleukin 8) is the only protein coinciding in the three pathways and present only in the PDAC group. This difference is more remarkable when evaluating the pathways of cytokine-cytokine receptor interaction and cytokines and growth factors, the latter in BRITE (Functional hierarchies of biological entities) tables, finding association in the presence of IL-8 with interleukin 11 (IL-11), CCL15 (Chemokine (C-C motif) ligand 15), CSF1 (Macrophage colony-stimulating factor) and CXCL7 (Chemokine (C-X-C motif) ligand 7) in the PDAC group ([Table 4](#T4){ref-type="table"}). Considering as an interaction point among prokaryotes and eukaryotes, Toll-like and NOD-like receptor pathways, we analyzed those signaling pathways and IL-8 was also present, and only in the PDAC group. In other KEGG signaling pathways with relevance to carcinogenesis processes such as DNA repair, xenobiotic metabolism, and pathways in cancer and pancreatic cancer, we didn\'t find differences. In the signaling pathways over-represented in exclusive and differentially abundant proteins, we could not find a clear biological meaning. In the WebGestal platform analysis, there were no relevant results for useful, therapeutic drugs using the Drugbank database.

###### 

Human total proteins per group in KEGG of bacterial infection over-represented signaling pathways.

  **Shigellosis** ***N*** **=** **20**   **Pertussis** ***N*** **=** **22**   **Legionellosis** ***N*** **=** **21**                                                                 
  -------------------------------------- ------------------------------------ ---------------------------------------- -------- ------------- --------------- -------- ------------- ---------------
  K04371                                 Gallstones:                          MK01_HUMAN                               K01330   Gallstones:   C1R_HUMAN       K01370   Gallstones:   
                                         Carcinoma:                           MK03_HUMAN                                        Carcinoma:    C1R_HUMAN                Carcinoma:    CASP1_HUMAN
  K04392                                 Gallstones:                          RAC1_HUMAN                               K01331   Gallstones:   C1S_HUMAN       K03231   Gallstones:   EF1A2_HUMAN
                                         Carcinoma:                           RAC1_HUMAN                                        Carcinoma:    C1S_HUMAN                Carcinoma:    EF1A2_HUMAN
  K04393                                 Gallstones:                          CDC42_HUMAN                              K01332   Gallstones:   CO2_HUMAN       K03233   Gallstones:   EF1G_HUMAN
                                         Carcinoma:                           CDC42_HUMAN                                       Carcinoma:    CO2_HUMAN                Carcinoma:    EF1G_HUMAN
  K04438                                 Gallstones:                          CRK_HUMAN                                K01370   Gallstones:                   K03283   Gallstones:   HS71B_HUMAN
                                         Carcinoma:                           CRK_HUMAN                                         Carcinoma:    CASP1_HUMAN              Carcinoma:    HS71B_HUMAN
  K04514                                 Gallstones:                                                                   K02183   Gallstones:   CALM3_HUMAN     K03990   Gallstones:   CO3_HUMAN
                                         Carcinoma:                           ROCK1_HUMAN                                       Carcinoma:    CALM3_HUMAN              Carcinoma:    CO3_HUMAN
  K05692                                 Gallstones:                          ACTB_HUMAN                               K03986   Gallstones:   C1QA_HUMAN      K04077   Gallstones:   CH60_HUMAN
                                         Carcinoma:                           ACTB_HUMAN                                        Carcinoma:    C1QA_HUMAN               Carcinoma:    CH60_HUMAN
  K05700                                 Gallstones:                          VINC_HUMAN                               K03987   Gallstones:   C1QB_HUMAN      K04391   Gallstones:   CD14_HUMAN
                                         Carcinoma:                           VINC_HUMAN                                        Carcinoma:    C1QB_HUMAN               Carcinoma:    CD14_HUMAN
  K05748                                 Gallstones:                          WASF2_HUMAN                              K03988   Gallstones:   C1QC_HUMAN      K05482   Gallstones:   IL18_HUMAN
                                         Carcinoma:                                                                             Carcinoma:    C1QC_HUMAN               Carcinoma:    IL18_HUMAN
  K05754                                 Gallstones:                          ARPC5_HUMAN                              K03989   Gallstones:   CO4A_HUMAN      K06461   Gallstones:   ITAM_HUMAN
                                         Carcinoma:                           ARPC5_HUMAN                                       Carcinoma:    CO4A_HUMAN               Carcinoma:    ITAM_HUMAN
  K05755                                 Gallstones:                          ARPC4_HUMAN                              K03990   Gallstones:   CO3_HUMAN       K06464   Gallstones:   
                                         Carcinoma:                           ARPC4_HUMAN                                       Carcinoma:    CO3_HUMAN                Carcinoma:    ITB2_HUMAN
  K05756                                 Gallstones:                          ARPC3_HUMAN                              K03994   Gallstones:   CO5_HUMAN       K07874   Gallstones:   RAB1A_HUMAN
                                         Carcinoma:                           ARPC3_HUMAN                                       Carcinoma:    CO5_HUMAN                Carcinoma:    RAB1A_HUMAN
  K05757                                 Gallstones:                          ARC1B_HUMAN                              K04001   Gallstones:   IC1_HUMAN       K07875   Gallstones:   RAB1B_HUMAN
                                         Carcinoma:                           ARC1B_HUMAN                                       Carcinoma:    IC1_HUMAN                Carcinoma:    RAB1B_HUMAN
  K05758                                 Gallstones:                          ARPC2_HUMAN                              K04002   Gallstones:   C4BPA_HUMAN     K07937   Gallstones:   ARF1_HUMAN
                                         Carcinoma:                           ARPC2_HUMAN                                       Carcinoma:    C4BPA_HUMAN              Carcinoma:    ARF1_HUMAN
  K05759                                 Gallstones:                          PROF1_HUMAN                              K04371   Gallstones:   MK01_HUMAN      K07953   Gallstones:   SAR1A_HUMAN
                                         Carcinoma:                           PROF1_HUMAN                                       Carcinoma:    MK03_HUMAN               Carcinoma:    SAR1A_HUMAN
  K06106                                 Gallstones:                          SRC8_HUMAN                               K04391   Gallstones:   CD14_HUMAN      K08517   Gallstones:   SC22B_HUMAN
                                         Carcinoma:                           SRC8_HUMAN                                        Carcinoma:    CD14_HUMAN               Carcinoma:    SC22B_HUMAN
  K06256                                 Gallstones:                          CD44_HUMAN                               K04513   Gallstones:   RHOA_HUMAN      K08738   Gallstones:   CYC_HUMAN
                                         Carcinoma:                           CD44_HUMAN                                        Carcinoma:    RHOA_HUMAN               Carcinoma:    CYC_HUMAN
  K07209                                 Gallstones:                          IKKB_HUMAN                               K04630   Gallstones:   GNAI2_HUMAN     K10030   Gallstones:   
                                         Carcinoma:                                                                             Carcinoma:    GNAI2_HUMAN              Carcinoma:    **IL8_HUMAN**
  K07863                                 Gallstones:                          RHOG_HUMAN                               K05765   Gallstones:   COF1_HUMAN      K10159   Gallstones:   TLR2_HUMAN
                                         Carcinoma:                           RHOG_HUMAN                                        Carcinoma:    COF1_HUMAN               Carcinoma:    
  K10030                                 Gallstones:                                                                   K06461   Gallstones:   ITAM_HUMAN      K12799   Gallstones:   
                                         Carcinoma:                           **IL8_HUMAN**                                     Carcinoma:    ITAM_HUMAN               Carcinoma:    ASC_HUMAN
  K12836                                 Gallstones:                          U2AF5_HUMAN                              K06464   Gallstones:                   K13525   Gallstones:   TERA_HUMAN
                                         Carcinoma:                           U2AF5_HUMAN                                       Carcinoma:    ITB2_HUMAN               Carcinoma:    TERA_HUMAN
                                                                                                                       K10030   Gallstones:                   K15464   Gallstones:   BNIP3_HUMAN
                                                                                                                                Carcinoma:    **IL8_HUMAN**            Carcinoma:    
                                                                                                                       K12799   Gallstones:                                          
                                                                                                                                Carcinoma:    ASC_HUMAN                              

*Kyoto Encyclopedia of Genes and Genomes. Bold indicates Interleukin-8*.

###### 

Comparison of human total proteins related to cytokine-cytokine receptor interaction and growth factors and cytokines signaling pathways.

  **Cytokine-cytokine receptor interaction** ***N*** **=** **12**   **Growth factors and cytokines** ***N*** **=** **8**                                        
  ----------------------------------------------------------------- ------------------------------------------------------ ------------- -------- ------------- -------------
  K04723                                                            Gallstones:                                            IL1AP_HUMAN   K05417   Gallstones:   
                                                                    Carcinoma:                                             IL1AP_HUMAN            Carcinoma:    IL11_HUMAN
  K05059                                                            Gallstones:                                            CNTFR_HUMAN   K05424   Gallstones:   LEP_HUMAN
                                                                    Carcinoma:                                                                    Carcinoma:    LEP_HUMAN
  K05060                                                            Gallstones:                                            IL6RB_HUMAN   K05450   Gallstones:   
                                                                    Carcinoma:                                             IL6RB_HUMAN            Carcinoma:    PDGFD_HUMAN
  K05062                                                            Gallstones:                                            LEPR_HUMAN    K05453   Gallstones:   
                                                                    Carcinoma:                                             LEPR_HUMAN             Carcinoma:    CSF1_HUMAN
  K05090                                                            Gallstones:                                            CSF1R_HUMAN   K05482   Gallstones:   IL18_HUMAN
                                                                    Carcinoma:                                                                    Carcinoma:    IL18_HUMAN
  K05417                                                            Gallstones:                                                          K05511   Gallstones:   
                                                                    Carcinoma:                                             IL11_HUMAN             Carcinoma:    CCL15_HUMAN
  K05424                                                            Gallstones:                                            LEP_HUMAN     K10029   Gallstones:   
                                                                    Carcinoma:                                             LEP_HUMAN              Carcinoma:    CXCL7_HUMAN
  K05453                                                            Gallstones:                                                          K10030   Gallstones:   
                                                                    Carcinoma:                                             CSF1_HUMAN             Carcinoma:    IL8_HUMAN
  K05482                                                            Gallstones:                                            IL18_HUMAN                           
                                                                    Carcinoma:                                             IL18_HUMAN                           
  K05511                                                            Gallstones:                                                                                 
                                                                    Carcinoma:                                             CCL15_HUMAN                          
  K10029                                                            Gallstones:                                                                                 
                                                                    Carcinoma:                                             CXCL7_HUMAN                          
  K10030                                                            Gallstones:                                                                                 
                                                                    Carcinoma:                                             IL8_HUMAN                            

*Kyoto Encyclopedia of Genes and Genomes*.

Bacterial Protein Analysis
--------------------------

Proportional participation in some taxonomic levels of the imputed protein species is summarized in [Table 5](#T5){ref-type="table"}. The total protein list was analyzed in KEGG Mapper Reconstruct Pathway focusing on: (1) signaling pathways related to prokaryote interaction, (2) g:Profiler over-represented pathways in human proteins and (3) over-represented pathways in a metagenomic inference analysis ([@B34]). The latter analysis was performed from a small microbiota survey within the 20 samples, using bile from the gallbladders of GS patients (*N* = 3), bile from the gallbladders of PDAC patients (*N* = 11) and common biliary brush over the tumor from PDAC patients (*N* = 11) as samples. The results of the analysis show two statistically significant over-represented pathways, pyrimidine deoxyribonucleotide biosynthesis and isoprene biosynthesis (unpublished results).

###### 

Average of the 5 most abundant taxonomic levels per group from identified total bacterial protein.

           **Group**                                         
  -------- --------------------- ----- --------------------- -----
  Phylum   Proteobacteria        60    Proteobacteria        64
           Firmicutes            15    Firmicutes            13
           Actinobacteria        7     Actinobacteria        6
           Cyanobacteria         4     Cyanobacteria         3
           Bacteroidetes         2,5   Thermotoga            2,8
  Class    Gammaproteobacteria   32    Gammaproteobacteria   38
           Alfaproteobacteria    16    Alfaproteobacteria    17
           Bacilli               10    Bacilli               8
           Actinobacteria        7     Betaproteobacteria    6,5
           Deltaproteobacteria   4     Clostridia            6
  Order    Enterobacterales      13    Enterobacterales      20
           Bacillales            7     Rhizobiales           6
           Rhizobiales           6,5   Clostridiales         5
           Clostridiales         5     Bacillales            4,5
           Pseudomonadales       4,5   Burkholderiales       4,5
  Family   Enterobacteriaceae    8,5   Enterobacteriaceae    13
           Bacillaceae           4,5   Pasteurellaceae       3,5
           Pseudomonadaceae      3,5   Erwiniaceae           3,2
           Geobacteraceae        3     Bacillaceae           3
           Mycobacteriaceae      2,5   Burkholderiaceae      3
  Genus    Escherichia           5     Shigella              5
           Bacillus              4     Escherichia           3
           Pseudomonas           3     Bacillus              2,5
           Geobacter             3     Salmonella            2,5
           Mycobacterium         2     Shewanella            2

*GS, gallstones; PDAC, pancreatic ductal adenocarcinoma*.

Upon comparison of the GS and PDAC total protein groups, we found qualitative and quantitative differences regarding quorum sensing, biofilm formation, antibiotic synthesis (biosynthesis of other secondary metabolites) and metabolism of terpenoids and polyketides ([Table 6](#T6){ref-type="table"}). Regarding metabolism of terpenoids and polyketides, there is a protein involved in zeatin biosynthesis (MIAA_PSECP) that stands out from the other proteins, as it is not present in the PDAC group, is not a protein with an antibiotic function and is specific to that metabolic pathway. Concerning the PDAC group, in the signaling pathway of terpenoid and polyketide metabolism, there is one protein related to surfactin biosynthesis (SRFAB_BACSU), which is also notable, since this protein is also involved in the quorum-sensing signaling pathway. The proteins involved in quorum sensing and biofilm formation show qualitative differences, and the number of proteins present in antibiotic biosynthesis are considerably higher in the PDAC group compared to the GS group. The analysis of bacterial proteins present in the three g:Profiler over-represented human protein signaling pathways related to bacterial infection in the total PDAC group, show no differences in KEGG Mapper Reconstruct Pathway.

###### 

Comparison of bacterial list of total proteins in prokaryote interaction signaling pathways and microbiota metagenomic inference over-represented pathways.

  **Metabolism of terpenoids and polyketides**                                                       
  -------------------------------------------------- ----------- -------------------- -------------- ------------------------------------------------------
  **GALLSTONES**                                                                                     
  ISPE_RHOP5                                         ispE        Proteobacteria       Negative       Terpenoid backbone biosynthesis
  ISPG_HAEIE                                         ispG        Proteobacteria       Negative       Terpenoid backbone biosynthesis
  ISPG_SHEON                                         ispG        Proteobacteria       Negative       Terpenoid backbone biosynthesis
  **MIAA_PSECP**                                     **miaA**    **Actinobacteria**   **Positive**   **Zeatin biosynthesis**
  FADJ_PECCP                                         fadJ        Proteobacteria       Negative       Limonene and pinene degradation Geraniol degradation
  TKT1_ECOLI                                         tktA        Proteobacteria       Negative       Biosynthesis of ansamycins
  **CARCINOMA**                                                                                      
  ISPE_RHOFT                                         ispE        Proteobacteria       Negative       Terpenoid backbone biosynthesis
  ISPG_GRABC                                         ispG        Proteobacteria       Negative       Terpenoid backbone biosynthesis
  **SRFAB_BACSU**                                    **srfAB**   **Firmicutes**       **Positive**   **Nonribosomal peptide structures**
  **Biosynthesis of others secondary metabolites**                                                   
  **Protein**                                        **Gen**     **Phylum**           **Gram**       **Pathway**
  **GALLSTONES**                                                                                     
  DAPB_STRAW                                         dapB        Actinobacteria       Positive       Monobactam biosynthesis
  **CARCINOMA**                                                                                      
  PROA_LEPBL                                         proA        Spirochaetes         Negative       Carbapenem biosynthesis
  PROA_ALKOO                                         proA        Firmicutes           Positive       Carbapenem biosynthesis
  DAPB_GEOKA                                         dapB        Firmicutes           Positive       Monobactam biosynthesis
  DAPB_STRAW                                         dapB        Actinobacteria       Positive       Monobactam biosynthesis
  DAPA_RHOFT                                         dapA        Proteobacteria       Negative       Monobactam biosynthesis
  PGCA_BACSU                                         pgcA        Firmicutes           Positive       Streptomycin biosynthesis
  HIS8_WOLSU                                         hisC        Proteobacteria       Negative       Novobiocin biosynthesis
  TRPE_THET8                                         trpE        Deinococcus          Negative       Phenazine biosynthesis
  **Cellular Community---Prokaryotes**                                                               
  **Protein**                                        **Gen**     **Phylum**           **Gram**       **Pathway**
  **GALLSTONES**                                                                                     
  SECA_LACAC                                         secA        Firmicutes           Positive       Quorum sensing
  SECA_CLOTH                                         secA        Firmicutes           Positive       Quorum sensing
  YIDC_METCA                                         yidC        Proteobacteria       Negative       Quorum sensing
  LUXS_DESPS                                         luxS        Proteobacteria       Negative       Quorum sensing, biofilm formation
  **CARCINOMA**                                                                                      
  SP0A_CLOBU                                         spo0A       Firmicutes           Negative       Quorum sensing
  SECA_CLOTH                                         secA        Firmicutes           Positive       Quorum sensing
  **SRFAB_BACSU**                                    **srfAB**   **Firmicutes**       **Positive**   **Quorum sensing**
  PTGA_SHIFL                                         crr         Proteobacteria       Negative       Biofilm formation
  TRPE_THET8                                         trpE        Deinococcus          Negative       Biofilm formation
  CHEB2_BURPS                                        cheB2       Proteobacteria       Negative       Biofilm formation

*Source: Kyoto Encyclopedia of Genes and Genomes. Bold indicates Bacterial proteins included in the carcinogenesis model*.

Discussion {#s4}
==========

To the best of our knowledge, this is the first study to compare human and bacterial proteins, using a metaproteomic approach, bile samples exposed to a tumor vs. non-tumor environment in human PDAC and GS patients, respectively. The characterization of a single species protein profile is known as proteomics, while the characterization of a multi-species protein profile is known as metaproteomics ([@B35]). The metaproteomic concept has been studied in humans through the characterization of fecal microbiota and the proteins produced by the different local bacterial species, enabling a better comprehension of the local conditions in the gastrointestinal tract ([@B36], [@B37]). In theory, the microenvironment within the biliary tract and the gallbladder will be more resistant to external variation and more accessible for bile retrieval in animal models. For all that, the biliary tract including its reservoir, will be an ideal biological system to evaluate through metaproteomic and microbiota analyses in conjunction, changes related to specific diets, neoplastic conditions, antibiotic use, chemotherapeutic schemas etc.

Finding meaningful biological information from omics\' science data sets has been one of the major challenges of science in recent years ([@B38]). The relevance of research findings cannot be measured in every biological instance using statistical significance alone, as not all statistically significant results translate into meaningful biological change. Accordingly, in some areas of science, in which we cannot use statistics, or for which we have not developed appropriate tools, we should look for procedural alternatives that at least enable us to explore the real biological value of data sets. In our research, the three g:Profiler over-represented pathways in human proteins show qualitative and quantitative coincidences and differences regarding the presence of certain proteins in the PDAC and GS groups. The detailed analysis of the proteins in each over-represented signaling pathway is the component of the analysis with the greatest importance. Due to the polyfunctionality of bacteria and human proteins, these proteins must be contextualized and analyzed for relevant biological pathways.

IL-8: Carcinogenesis and Prokaryote Interactions
------------------------------------------------

IL-8 was identified as a common protein in the three g:Profiler over-represented signaling pathways in PDAC human total proteins, associated with bacterial infections. IL-8 is a human chemotactic interleukin of the C-X-C family also known as CXCL8, originally discovered in macrophages ([@B39]), but also produced by epithelial cells. The effect of IL-8 depends on its interaction with specific membrane receptors coupled to G proteins CXCR1 (C-X-C motif chemokine receptor 1, C-X-C) and CXCR2 (C-X-C motif chemokine receptor 2) ([@B40]). Under physiological conditions IL-8 levels are undetectable, increasing in the presence of other pro-inflammatory cytokines like tumor necrosis factor α (TNFα) and interleukin 1β ([@B41], [@B42]). None of the latter two cytokines were identified in the PDAC or GS group, suggesting that alternative pathways can stimulate IL-8 synthesis.

High levels of IL-8 are described as poor outcome predictors in many malignant neoplasms, including PDAC. The cellular endpoint effects induced by the IL-8 CXCR1/CXCR2 axis, in normal epithelial cells, tumor cells or other cells in the tumor microenvironment, promote cellular survival, proliferation, angiogenesis, and a stem cell phenotype ([@B43], [@B44]). Concordantly, high levels of IL-8 in patients with breast, prostate and lung carcinoma, and melanoma are related to aggressive tumor behavior, due to high proliferation rate, local invasion, angiogenesis, and an increase of a stem cell phenotype and metastasis ([@B45]). In the special case of PDAC, high levels of IL-8 are also related to aggressive tumor behavior and poor prognosis, with evidence that includes PDAC cell line models ([@B46]), high blood levels in PDAC and cholangiocarcinoma patients ([@B47], [@B48]), and over-expression of IL-8 and its receptors in tumor tissue ([@B49]) and inflammatory cells infiltrating the tumor ([@B50]).

The biological relevance of IL-8 is not limited to neoplasms; there is a special prokaryote behavior linked to the synthesis of this interleukin. Biofilm formation by bacteria such as *F. nucleatum* and *A. naeslundii*, and not the planktonic form, stimulates the synthesis of IL-8 by human squamous epithelial cells ([@B51]). Supporting the latter concept, several surveys have proved that bacteria biofilm not only stimulates IL-8 synthesis by human squamous epithelial cells, but that stimulation is stronger when the biofilm is formed by multiple bacterial species ([@B52], [@B53]). Furthermore, the similarity of some amino acids in the carboxy-terminal region of IL-8 with cecropins, proteins with antibiotic properties, elicit the analysis of the antibiotic properties of IL-8 through the synthesis of synthetic peptides. These synthetic peptides are thought to be physiologically generated from acidic hydrolysis, and effectively have antibiotic properties which vary according to salt concentration and pH ([@B54]).

Some of the PDAC-specific proteins associated with IL-8 are also considered as poor outcome biomarkers in the natural history of malignant neoplasms. High levels of CXCL7 in cholangiocarcinoma tumoral tissue are associated with poor tumor differentiation, local lymph node metastasis, and lymphatic/vascular invasion ([@B55]). In renal carcinoma, high levels of CXCL7 are proposed as prognostic factors of chemotherapeutic response ([@B56]), and in colon cancer are related to poor survival in patients with liver metastasis ([@B57]). Similarly, high levels of CCL17 and IL-11 are associated with poor outcome in malignant neoplasms due to aggressive biological behavior regarding local invasion and metastasis ([@B58]--[@B61]).

Differences in Prokaryote Interaction Pathways
----------------------------------------------

The metagenomic inference analysis results from the small microbiota group revealed some over-represented pathways. Of special interest is the metabolism of terpenoids and polyketides signaling pathway. This pathway was analyzed using the total list of bacterial proteins, finding qualitative and quantitative differences, among them the presence of zeatin in the GS group and surfactin in the PDAC group. Terpenoids and polyketides are a huge group of substances synthesized by bacteria, fungi, plants, and animals. Zeatin is an isoprenoid derived from adenine with two isoforms, trans and cis, depending on which of the two hydroxyl groups in the lateral chain of isopentenyl is hydroxylated ([@B62]). The identified bacterial protein in the GS group participates in the metabolic pathway for *cis*-zeatin synthesis and is specific to this metabolic pathway. Cis-zeatin is a cytokinin that can be produced by multiple bacterial species ([@B63], [@B64]), with just one published piece of research evaluating its activity in tumor cell lines, proving its anti-tumor potential in leukemia cell lines ([@B65]).

The ability to produce surfactin is a property of bacteria from the genus Bacillus, and since the discovery of surfactin in 1968 by Arima, this amphipathic lipopeptide has been found to possess several properties ([@B66]). Within these properties are those general to all lipopeptides and antibacterial proteins which act upon Gram-positive and Gram-negative bacteria ([@B67], [@B68]), and other anti-inflammatory ([@B69]) and anti-viral effects ([@B70]). Of interest in our research, the properties associated with biofilm formation are of utmost importance. Regarding biofilm formation, surfactin has a selective effect, primarily inhibitory, over many bacterial species, though to date there is no clear biological explanation for the selectivity of surfactin for biofilm production/inhibition ([@B71]--[@B73]).

Besides producing essential compounds for survival, bacteria are able to produce and secrete into the environment low molecular weight compounds called secondary metabolites. Within those secondary metabolites are substances with antibiotic properties that, in a specific microenvironment, confer an advantage upon the bacterium producing the antibiotics, reducing the number of competitors (mainly for nutrient acquisition) ([@B74]). Bacterial antibiotic synthesis is a phenomenon influenced by the community and denotes a competitive behavior for survival, and is seemingly species-specific ([@B75]). In our analysis, the increased number of identified proteins in the antibiotic synthesis pathways in the PDAC group compared to the GS group is remarkable. Based on that fact, we infer a major competition among species in the PDAC group.

The change in bacteria association, from free-living or planktonic to biofilm formation, relies upon many genetic factors and local conditions ([@B76]). Biofilm formation is tightly associated in multiple bacterial species with the increase of c-di-GMP (cyclic diguanylate) intracellular levels, which can also be induced by quorum sensing proteins ([@B77]). By means of conventional microbiota analysis, we are unable to determine if the identified bacteria are in a biofilm or not. For this reason, we considered that finding different bacterial proteins among the groups (PDAC and GS) related to quorum sensing and biofilm formation is of biological relevance, as these proteins can be involved in the process of bacteria-induced carcinogenesis. Inflammation is considered a starting point of bacteria associated carcinogenesis. However, this physio-pathological mechanism cannot fully explain the development of carcinomas in the gastrointestinal and biliary tract, as inflammatory states constantly occur throughout the human lifespan, and only a few human beings develop malignant neoplasms in the gastrointestinal system. The bacteria-cancer relationship has been viewed in a reductionist manner as simply a pro-inflammatory milieu initiated by bacteria, in line with the hypothesis of inflammation and cancer proposed by Virchow in 1835 ([@B78]). Previous studies have proposed that this pro-inflammatory milieu may be initiated by dysbiosis, which is defined as a change in the normal composition of the microbiota. However, dysbiosis has neither fulfilled the expectations nor provided---to date---a reliable molecular explanation for bacteria-induced carcinogenesis ([@B79]).

The Carcinogenesis Model
------------------------

We hypothesized that there is no such thing as a dysbiotic microbiota, regarding the presence or absence of certain bacterial species. A dysbiotic microbiota is a haphazard composition of bacterial species with products harmful to bacteria and epithelial cells, specific to a particular individual vis-à-vis microbiota-modifying factors. Based on our metaproteomic findings regarding bacterial and human proteins, and its associations, we proposed a biliary tract carcinogenesis model. We are aware of that our proteomic analysis is a snapshot of established PDAC cases, and the propose bacteria-induced carcinogenesis model for the biliary tract is still speculative, not validated, and therefore must be interpreted with caution ([Figure 3](#F3){ref-type="fig"}). The model initiates with unique or multiple dysbiotic factors that promote repeated inflammatory events ([@B80]), classically described as stones in the biliary tract, tobacco use, obesity, diabetes mellitus or genetic factors ([@B81]). Those promoting factors change the usual biliary tract bacteria composition expected for that individual, shaped according to diet, genetic background, sex, race, age, etc. Promoting factors can create many unusual microbiotas for that individual; though the specific carcinogenic dysbiotic microbiota has a reduced diversity as a sign of competition fostered by highly elevated synthesis of antibiotic products, and qualitative and quantitative differences in bacterial proteins associated with quorum sensing and biofilm formation, such as zeatin and surfactin. High levels of antibiotics maintain the dysbiotic environment, added to the antibiotic effect of surfactin, the latter also selecting, through inhibition, bacteria for biofilm formation. Bacterial species capable of biofilm formation will promote the synthesis of IL-8 by biliary tract epithelial cells. Fragments of IL-8 with antibiotic potential also contribute to maintaining dysbiosis, while the whole protein exerts its pro-neoplastic function of epithelial cellular survival, proliferation, angiogenesis, invasion and stem cell phenotype. The described scenario in conjunction with low levels or absence of zeatin, an anti-neoplastic protein, facilitates the progression of epithelial changes from low-grade dysplasia to adenocarcinoma, through mutation aggregation ([@B82]--[@B84]). The dysbiotic and harmful epithelial microenvironment needs to continue for a long but unspecified period of time to transform a benign epithelial cell into a malignant one, a period in which the molecular characteristic may be detected.

![Proposed Model of Biliary Tract Bacterial-Induced Carcinogenesis. The figure depicts a harmful microenvironment originating from prokaryote and eukaryote interaction. The harmful microenvironment initiates with a dysbiotic microbiota product of repetitive inflammatory processes induced by risk factors. The dysbiotic microbiota is specific for low levels of zeatin and high levels of antibiotics (ATB) and surfactin. Surfactin selectively inhibits bacterial biofilm formation---to date---without a molecular explanation for this selectivity. Bacterial biofilm formation stimulates IL-8 (interleukin 8) pro-neoplastic cytokine synthesis by biliary tract epithelial cells. Antibiotics, surfactin, and fragments of IL-8 with antibiotic properties perpetuate the dysbiotic microenvironment. Mutations accumulate in epithelial cells and IL-8 promotes the progression of dysplastic changes to adenocarcinoma, in low zeatin anti-neoplastic protein levels. ATB, antibiotics; IL-8, interleukin 8; QS, quorum sensing proteins.](fonc-10-01032-g0003){#F3}

There are no clear indications for sample size calculations in proteomics research, and the results from a specific protein extraction method, imputation pipeline, and bioinformatic analysis must be validated in further *in vitro* and *in vivo* investigations. Microbiota analysis and dysbiosis alone have not answered the question of the bacteria-induced pathology model. Future research may concentrate on improving the throughput of protein identification from complex biological fluids like bile and consider a combined microbiota and metaproteomic approach to analyze bacterial communities and bacterial and human proteins. It is necessary to start thinking of a change in the dysbiosis paradigm, as we hypothesized dysbiosis is not a specific bacterial composition but rather a harmful protein microenvironment that can be created by several "dysbiotic" microbiotas.
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